ACA
Avoro Capital Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $40.3M | Sell |
4,500,000
-4,200,000
| -48% | -$37.6M | 0.71% | 25 |
|
|
2025
Q1 | $65.3M | Sell |
8,700,000
-3,165,000
| -27% | -$23.7M | 1.02% | 20 |
|
|
2024
Q4 | $89.2M | Hold |
11,865,000
| – | – | 1.26% | 21 |
|
|
2024
Q3 | $90.2M | Sell |
11,865,000
-705,000
| -6% | -$5.36M | 1.31% | 19 |
|
|
2024
Q2 | $77.7M | Sell |
12,570,000
-480,000
| -4% | -$2.97M | 1.03% | 24 |
|
|
2024
Q1 | $66.3M | Hold |
13,050,000
| – | – | 0.77% | 28 |
|
|
2023
Q4 | $78.2M | Buy |
13,050,000
+1,500,000
| +13% | +$8.99M | 1.08% | 21 |
|
|
2023
Q3 | $81.8M | Sell |
11,550,000
-505,000
| -4% | -$3.58M | 1.28% | 17 |
|
|
2023
Q2 | $84.9M | Buy |
12,055,000
+1,635,000
| +16% | +$11.5M | 1.15% | 20 |
|
|
2023
Q1 | $86.9M | Buy |
10,420,000
+1,370,000
| +15% | +$11.4M | 1.29% | 19 |
|
|
2022
Q4 | $104M | Hold |
9,050,000
| – | – | 1.55% | 16 |
|
|
2022
Q3 | $114M | Buy |
9,050,000
+2,550,000
| +39% | +$32.1M | 2.11% | 13 |
|
|
2022
Q2 | $68.8M | Buy |
6,500,000
+4,625,000
| +247% | +$48.9M | 1.36% | 17 |
|
|
2022
Q1 | $30.5M | Buy |
+1,875,000
| New | +$30.5M | 0.56% | 28 |
|
|
2018
Q1 | – | Sell |
-340,821
| Closed | -$1.67M | – | 51 |
|
|
2017
Q4 | $1.67M | Sell |
340,821
-1,437,704
| -81% | -$7.06M | 0.11% | 41 |
|
|
2017
Q3 | $9.32M | Sell |
1,778,525
-175,000
| -9% | -$917K | 0.72% | 27 |
|
|
2017
Q2 | $10.9M | Buy |
1,953,525
+350,524
| +22% | +$1.95M | 1.37% | 21 |
|
|
2017
Q1 | $13.5M | Sell |
1,603,001
-28,501
| -2% | -$239K | 1.72% | 20 |
|
|
2016
Q4 | $10.3M | Buy |
1,631,502
+252,100
| +18% | +$1.6M | 2.09% | 19 |
|
|
2016
Q3 | $6.08M | Buy |
+1,379,402
| New | +$6.08M | 1.07% | 25 |
|